[Articles] Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
Phase 3positivederamiocelPositive
AI Analysis
Summary
Deramiocel, a heart-derived cellular therapy, demonstrated positive Phase 3 results in the HOPE-3 trial, safely slowing disease progression in advanced Duchenne muscular dystrophy and preserving skeletal muscle function with a simple quarterly outpatient regimen.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Deramiocel safely slows disease progression in advanced DMD, preserving skeletal muscle function
Importance:8/10
Sentiment:
0.75
Phase 3DMDcellular therapypositive datarare disease
Read the original article
Published by The Lancet on July 29, 2026 2:00 PM